Pulmatrix Inc.
This article was originally published in Start Up
Executive Summary
Originally intent on developing a contagion-prevention product for biodefense, Pulmatrix Inc. now has much larger ambitions. The company believes its new technologies for formulating drugs as dry powders and delivering them via inhalers will make its lead respiratory drug candidate more convenient and potent. Pulmatrix also sees the methods as a discovery engine likely to give rise to partnerships and branded generics.
You may also be interested in...
Pulmatrix Takes $14 Mil. From Insiders, Sharpens Focus On Dry-Powder Inhaler Drug
With the Series B extension, the company will conduct Phase Ib and IIa studies in COPD and cystic fibrosis, while aiming to partner one indication.
Pulmatrix Takes $14 Mil. From Insiders, Sharpens Focus On Dry-Powder Inhaler Drug
With the Series B extension, the company will conduct Phase Ib and IIa studies in COPD and cystic fibrosis, while aiming to partner one indication.
Start-Up Previews
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Respiratory Therapies: Moving Beyond Symptomatic Relief," features profiles of Pearl Therapeutics, Protectimmun and Pulmatrix. Plus these Start-Ups Across Health Care: 3WIN, Cianna Medical, GlySure and Promedior.